Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NimaGen logo — Sequencing. Simpler. Smarter. Safer.

NimaGen

Sequencing. Simpler. Smarter. Safer.

Founded 2011 The Netherlands The Netherlands 24 employees Biotechnology

General Information

Company Name NimaGen
Founded Year 2011
Location The Netherlands The Netherlands
Employees 24
Industries Biotechnology
Offices as of Sep 2026
NL Gelderland Nijmegen 6545 AB, NL Gelderland Nijmegen 6545 AB
Social

BounceWatch is an independent company data service, not affiliated with NimaGen. To contact NimaGen, visit nimagen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 21, 2026

A collaboration between NimaGen and 1928 Diagnostics for a webinar on microbiome sequencing and analysis was announced.

Product Launch Sep 02, 2026

NimaGen has launched the EasySeq™ DuoBiome Library Prep Kit, enabling combined bacterial and fungal microbiome profiling from the same samples for NGS.

Get alerts when NimaGen shows new signals

About NimaGen

NimaGen is a pioneering company within the biotechnology industry, operating as part of the Dutch Biolegio Holding since its establishment in 2011. The company has gained significant recognition for its provision of pre-designed tests, reagents, and workflow solutions for Sanger Sequencing and NGS Library Prep by Reverse Compliment PCR. NimaGen's strong focus on serving molecular biology laboratories globally aligns with its mission of enabling informed decision-making and creating value for customers across various sectors, including clinical research, forensics, agriculture, food safety, and environmental hygiene. The company's contributions have been particularly noteworthy in the ongoing fight against COVID-19, where its products played a crucial role in facilitating the rapid and accurate tracking of emerging variants of the coronavirus, such as Delta en Omicron BA.2, BA.4 and BA.5. NimaGen has positioned itself as a key player in addressing the current global health challenges. With an emphasis on innovation and efficiency, NimaGen's implementation of patented Reverse Compliment PCR (RC-PCR) technology reflects its commitment to providing advanced NGS Library Prep workflows. This unique approach allows for simultaneous multiplex target amplification and NGS indexing in a single, closed tube PCR assay, catering to diverse applications from genotyping to ultra-sensitive mutation detection. NimaGen's product portfolio includes renowned brands such as EasySeq™, IDseek®, BrilliantDye™, NimaPOP™, D-Pure™, iX-Pure™, ExS-Pure™, Alpaqua®, Biolegio, and AmpliClean™. The company's extensive range of offerings underscores its versatility and expertise in meeting the evolving needs of the biotechnology sector. With its headquarters based in The Netherlands, NimaGen's global outreach is further enhanced by its resourceful specialists, who can be contacted via email at [email protected] or through their official websites, www.nimagen.com and www.rcpcr.com. The company also actively engages with its audience through Instagram (@nimagen) and LinkedIn (@NimaGen), leveraging social platforms to foster connectivity and knowledge-sharing within the industry. NimaGen presents a compelling opportunity for potential investors seeking to support a forward-thinking, impactful player in the biotechnology landscape.

Taxonomy: DNA sequencing, NGS Library Prep, Reverse Compliment PCR, COVID-19 testing, Molecular biology, Genotyping, Mutation detection, SARS-CoV2, Forensic DNA analysis, Clinical research, Virology, Biolegio Holding, Sanger Sequencing, Genetic testing, Laboratory equipment

No funding data available for NimaGen yet.

NimaGen Alternatives & Competitors

NimaGen vs
TwinStrand Biosciences
TwinStrand Biosciences

Ultra-rare variants are detected with unparalleled sensitivity and specificity with TwinStrand Duple...

Venture round
24 employees
Biotechnology, Health Care
NimaGen vs
seqWell
seqWell United States

NGS Library Prep Simplified

Venture round
40 employees
Biotechnology, Life Sciences
Compare NimaGen vs seqWell
NimaGen vs
DNA ConneXions
DNA ConneXions United States

Empowering you to take control of your health

6 employees
Biotechnology, Health Care

FAQ About NimaGen

Sequencing. Simpler. Smarter. Safer.
NimaGen was founded in 2011.
NimaGen is headquartered in The Netherlands. As of Sep 2026, it also has offices in NL Gelderland Nijmegen 6545 AB, NL Gelderland Nijmegen 6545 AB.
NimaGen operates in Biotechnology. Its work centres on DNA sequencing, NGS Library Prep, Reverse Compliment PCR and COVID-19 testing.
NimaGen has approximately 24 employees.
Top alternatives and competitors to NimaGen include TwinStrand Biosciences, seqWell, DNA ConneXions, Loop Dee Science, Omixon. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NimaGen and TwinStrand Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NimaGen, https://bouncewatch.com/company/nimagen, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes